Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Akero Therapeutics in a research note issued to investors on Monday, January 27th. HC Wainwright analyst E. Arce expects that the company will post earnings of $5.58 per share for the year. HC Wainwright has a "Buy" rating and a $72.00 price objective on the stock. The consensus estimate for Akero Therapeutics' current full-year earnings is ($3.96) per share.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.15).
Other research analysts also recently issued research reports about the stock. Citigroup boosted their price objective on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a report on Tuesday. Morgan Stanley upped their price target on Akero Therapeutics from $46.00 to $96.00 and gave the company an "overweight" rating in a report on Tuesday. Finally, Canaccord Genuity Group raised their target price on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $61.57.
Get Our Latest Report on AKRO
Akero Therapeutics Stock Performance
AKRO stock traded up $2.09 on Wednesday, reaching $53.56. 2,046,554 shares of the company were exchanged, compared to its average volume of 2,078,760. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics has a 12 month low of $15.32 and a 12 month high of $58.40. The stock's fifty day moving average price is $29.31 and its 200 day moving average price is $28.51. The firm has a market capitalization of $3.74 billion, a PE ratio of -14.32 and a beta of -0.19.
Institutional Trading of Akero Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AKRO. American Century Companies Inc. bought a new position in shares of Akero Therapeutics in the 2nd quarter valued at about $347,000. Renaissance Technologies LLC acquired a new position in Akero Therapeutics in the second quarter valued at approximately $565,000. The Manufacturers Life Insurance Company boosted its stake in Akero Therapeutics by 26.1% in the second quarter. The Manufacturers Life Insurance Company now owns 107,172 shares of the company's stock valued at $2,514,000 after acquiring an additional 22,195 shares during the last quarter. Handelsbanken Fonder AB grew its holdings in Akero Therapeutics by 12.4% during the 3rd quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company's stock worth $574,000 after acquiring an additional 2,200 shares during the period. Finally, Creative Planning bought a new stake in shares of Akero Therapeutics during the 3rd quarter valued at $371,000.
Insider Transactions at Akero Therapeutics
In other news, COO Jonathan Young sold 50,716 shares of Akero Therapeutics stock in a transaction on Friday, November 1st. The stock was sold at an average price of $31.57, for a total value of $1,601,104.12. Following the completion of the sale, the chief operating officer now directly owns 216,286 shares of the company's stock, valued at approximately $6,828,149.02. This trade represents a 18.99 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Catriona Yale sold 9,061 shares of the business's stock in a transaction on Friday, November 15th. The stock was sold at an average price of $27.73, for a total value of $251,261.53. Following the sale, the insider now owns 74,158 shares of the company's stock, valued at approximately $2,056,401.34. The trade was a 10.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 257,620 shares of company stock valued at $8,076,127 in the last three months. 7.94% of the stock is owned by corporate insiders.
About Akero Therapeutics
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
See Also
Before you consider Akero Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akero Therapeutics wasn't on the list.
While Akero Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
